Subject 6 was a 40 year-old man with a 16-year history of inflammation in both eyes whose 1 1 5 extensive diagnostic work-up in Germany and the U.S. had been unrevealing (Table 1 and Figure   1 1 6 1A). In 1993 he had a three-day febrile illness accompanied by a rash that spread from his back to 1 1 7 his extremities. He was diagnosed with anterior uveitis of the left eye in 1999 and in 2001, 1 1 8 developed anterior uveitis of the contralateral eye. Topical steroid and non-steroidal anti-1 1 9 inflammatory drops were ineffective. Oral steroids were added in 2009 followed by methotrexate.
2 0
His inflammation did not improve after one year of combined immunotherapy, and his medications 1 2 1 were discontinued. results, suspicion for viral infection remained high. Antiviral therapy was initiated and continued for 1 3 0 three years ( Figure 1A ), but failed to curb the inflammation. In 2014 he had a paracentesis of the 1 3 1 right eye and a therapeutic vitrectomy of the left eye. Repeat infectious disease diagnostics were 1 3 2 unrevealing ( Figure 1A ). in Germany, Italy, and the United Kingdom in the early 1990s. Thus, this subject's RV strain is 1 6 4 temporally and geographically most proximate to the RV strain that was known to be circulating 1 6 5 when he developed a rash and fever in 1993 in Germany. that causes transient body rash and fever in healthy adults but can also cause devastating birth 1 8 8 defects. 23 RV has also been associated with Fuchs uveitis syndrome (FUS), a rare form of chronic 1 8 9 intraocular inflammation most often characterized by mild anterior chamber reaction, iris atrophy 1 9 0 with or without heterochromia, late onset ocular hypertension, and minimal associated visual 1 9 1 complaints. 17, 24, 25 In a subset of FUS patients, either RV IgG or RV RNA has been detected in 1 9 2 ocular fluid by Goldmann-Witmer coefficient analysis or respectively. 17, 24, 26 These tests The protracted diagnostic challenge in our subject is three-fold: (1) diagnostic tests are lacking for 1 9 7 ocular inflammation, (2) the subject's clinical findings were not consistent with FUS until many 1 9 8 years after disease onset, and (3) the subject's relevant infectious exposure occurred six years prior 1 9 9 to the onset of his ocular symptoms. This case highlights the advantage of an hypothesis-free 2 0 0 approach in which a single MDS assay can detect a multitude of pathogens that may or may not 2 0 1 have been previously associated with a particular clinical syndrome. Our subject's ocular inflammation predated his measles, mumps and rubella (MMR) vaccination by 2 0 7 seven years, and his RV strain most closely matched the strain circulating in his home country of 2 0 8 Germany at the time of his rash and fever in 1993, and not the vaccine strain ( Figure 2B ). This is 2 0 9 consistent with the notion that RV likely seeded his eyes during this primary infection. Although his 2 1 0 immune system cleared the infection peripherally, RV sequestered in the ocular compartment and 2 1 1 persisted presumably due to relative immune privilege. Indeed, our analysis of the RV genome 2 1 2 provides the first molecular evidence for active RV replication in FUS. Ocular RNA virus 2 1 3 sequestration is not a phenomenon relating solely to RV, as Ebola virus was recently detected in the 2 1 4 ocular fluid of a patient nine weeks after resolution of his viremia. 4 Using RT-PCR for RV on our 2 1 5 subject's tears, we were not able to detect shedding of RV, although longitudinal studies are 2 1 6 required to determine whether intermittent shedding through tears can occur. As we devise 2 1 7 strategies to rapidly identify and control emerging and re-emerging infectious diseases, expanding 
